Drug intelligence / Profile preview

Coxonil

Development stage: Unknown
Lead developer: Pillcraft
Administration: Oral

Overview

Coxonil is an Ayurvedic polyherbal dietary supplement developed and manufactured by Pillcraft (Pillcraft Private Limited) to support joint and bone health. It is formulated to manage bone degenerative conditions such as osteoarthritis and osteoporosis, alleviate joint pain and inflammation, and improve overall mobility. The supplement contains standardized extracts of traditional Ayurvedic herbs, including Sallaki (*Boswellia serrata*), Hadjod (*Cissus quadrangularis*), Ashwagandha (*Withania somnifera*), Gorakhmundi (*Sphaeranthus indicus*), Shatavari (*Asparagus racemosus*), and Ginger (*Zingiber officinale*).

Brand names: Coxonil

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)HSP90 (Heat shock protein 90 chaperone complex)ALOX12 (Arachidonate 12-lipoxygenase, 12S type)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Coxonil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coxonil.

Explore the full profile